Immunohistochemistry (IHC) Market Size, Demand, Share and Business Opportunities 2030

Immunohistochemistry (IHC) Market Size, Share & Trends Analysis By Product, By Application, By End-Users, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030

Published: Mar-2022	Report ID: BIOT2205	Pages: 1 - 223	Formats^*:
Category : Biotechnology

Global Immunohistochemistry Market Overview:

According to SPER Market Research, the Immunohistochemistry Market is estimated to reach USD 5.8 billion by 2030 with a CAGR of 6.5%. Increase in geriatric population, prevalence of infectious disease, advanced technology, increase in the funding, investment in research & development; these are the key to the expansion of this market.

Impact of COVID-19 on the Immunohistochemistry Market:

The outbreak of COVID-19 increased the investment in research to find out more effective treatment for it, so big Pharma companies came into field.

Scope of the report:

Report Metric	Details
Market size available for years	2019-2030
Base year considered	2021
Forecast period	2022-2030
Segments covered	By Product, By Application, By End Users, By Region
Geographies covered	North America, Europe, Asia Pacific, Latin America , Middle East, Africa
Companies Covered	Abcam plc, Agilent Technologies, Inc., Becton, Bio SB, Inc., Biocare Medical, LLC, Biogenex Laboratories, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, BioVision Inc., CANDOR Bioscience GmbH, Cell Signalling Technology, Inc., Danaher Corporation, Diagnostic Biosystems, Inc., Dickinson and Company, Eagle Biosciences, Inc., Elabscience, Inc., F. Hoffman-La Roche AG, Genemed Biotechnologies, Inc.,Merck KGaA , Miltenyi Biotec, PerkinElmer, Inc., PHC Holdings Corporation, Rockland Immunochemicals, Inc., Sakura Finetek Japan Co., Ltd., Takara Bio, Inc., Thermo Fisher Scientific, Inc.

Driver: Geriatric population & prevalence of infectious disease

There is increase in the geriatric population in low, medium, high-income countries as well, the intense prevalence of chronic infectious disease globally; there by increasing the expansion of this market.

Restraints: Intense Consolidation

The Immunohistochemistry Market is highly consolidated with few market players, patent expiry, government pressure in terms of price, less outcome in research & development; are the restraints of this market.

Get more information on this report: Download Free Sample PDF

Opportunity: choice for Personalized Medicine

The choices for personalized medicine have been increased, Immunohistochemistry helps in the personalization of medicines, and the low cost of Immunohistochemistry technique is the ideal for the treatment of cancer.

Challenges: Unskilled Professional

There is lack of skilled personnel in the laboratory, those who are there almost at the verge of retirement.

Global Immunohistochemistry Market Segmentation:

By Product: Antibodies (Primary antibodies, Secondary antibodies), Reagents (Blocking Sera and Reagents, Chromogenic Substrates, Diluents, Fixation Reagents, Histological Stains, Organic Solvents, Other Reagents, Proteolytic Enzymes), Equipment ( Slide Scanners, Slide-staining Systems, Tissue Processing Systems, Other Equipment ), Kits (IHC Kits for Animal tissue, IHC Kits for Human tissue).

By Application: Diagnostic applications (Autoimmune diseases, Cancer, Infectious diseases, Nephrological diseases, Neurological diseases, other diseases), Research applications (Drug development and Testing, stem cell research and developmental biology), Forensic applications.

By End-Users: Academic & research Institutes, Hospitals & Diagnostic Laboratories, Other end users (CROs, Pharma & biopharma companies, and forensic laboratories)

By Region: North America dominates the biggest share of the Immunohistochemistry Market; due to advanced economy, technological advancement, geriatric population, supportive reimbursement policies, effective government initiatives, investment on research & development. Asia Pacific has top expansion in this market due to increase investment in healthcare infrastructure, rising disposal income, invest by big Pharma companies.

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Market Dynamics

4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges

4.3. COVID-19 Impact on the Immunohistochemistry Market
4.4. Market Trends

5. Global Immunohistochemistry Market, by Product, 2019-2030 (USD Million)

5.1. Antibodies

5.1.1. Primary antibodies
5.1.2. Secondary antibodies

5.2. Reagents

5.2.1. Blocking Sera and Reagents
5.2.2. Chromogenic Substrates
5.2.3. Diluents
5.2.4. Fixation Reagents
5.2.5. Histological Stains
5.2.6. Organic Solvents
5.2.7. Other Reagents
5.2.8. Proteolytic Enzymes

5.3. Equipment

5.3.1. Slide Scanners
5.3.2. Slide-staining Systems
5.3.3. Tissue Processing Systems
5.3.4. Other Equipment

5.4. Kits

5.4.1. IHC Kits for Animal tissue
5.4.2. IHC Kits for Human tissue

6. Global Immunohistochemistry Market, by Application, 2019-2030 (USD Million)

6.1. Diagnostic applications

6.1.1. Autoimmune diseases
6.1.2. Cancer
6.1.3. Infectious diseases
6.1.4. Nephrological diseases
6.1.5. Neurological diseases
6.1.6. Other diseases (ophthalmic, cardiovascular, dermatological, and dental diseases)

6.2. Research applications

6.2.1. Drug development and Testing
6.2.2. Other research applications (stem cell research and developmental biology)

6.3. Forensic applications

7. Global Immunohistochemistry Market, by End-Users, 2019-2030 (USD Million)

7.1. Academic & research Institutes
7.2. Hospitals & Diagnostic Laboratories
7.3. Other end users (CROs, pharma & biopharma companies, and forensic laboratories)

8. Global Immunohistochemistry Market, by Region, 2019-2030 (USD Million)

8.1. North America

8.1.1. US
8.1.2. Canada

8.2. Europe

8.2.1. France
8.2.2. Germany
8.2.3. Italy
8.2.4. Spain
8.2.5. Rest of the Europe

8.3. Asia Pacific

8.3.1. China
8.3.2. India
8.3.3. Japan
8.3.4. Rest of Asia Pacific

8.4. Latin America
8.5. Middle East
8.6. Africa

9. Competitive Landscape

9.1. Introduction
9.2. Market Share Analysis, By Key Players
9.3. Competitive Scenario

9.3.1. Product Launches
9.3.2. Partnerships, Collaborations and Agreements
9.3.3. Acquisitions
9.3.4. Expansions
9.3.5. Other Developments

10. Company Profiles

10.1. Abcam plc
10.2. Agilent Technologies, Inc.
10.3. Becton
10.4. Bio SB, Inc.
10.5. Biocare Medical, LLC
10.6. Biogenex Laboratories
10.7. Bio-Rad Laboratories, Inc.
10.8. Bio-Techne Corporation
10.9. BioVision Inc.
10.10. CANDOR Bioscience GmbH
10.11. Cell Signalling Technology, Inc.
10.12. Danaher Corporation
10.13. Diagnostic Biosystems, Inc.
10.14. Dickinson and Company
10.15. Eagle Biosciences, Inc.
10.16. Elabscience, Inc.
10.17. F. Hoffman-La Roche AG
10.18. Genemed Biotechnologies, Inc.
10.19. Merck KGaA
10.20. Miltenyi Biotec
10.21. PerkinElmer, Inc.
10.22. PHC Holdings Corporation
10.23. Rockland Immunochemicals, Inc.
10.24. Sakura Finetek Japan Co., Ltd.
10.25. Takara Bio, Inc.
10.26. Thermo Fisher Scientific, Inc.

11. Appendix

SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.

The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.

SPER-Methodology-1